In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly's Asset Management Program

Executive Summary

Eli Lilly & Co.'s recent explosion of dealmaking in the seemingly disparate areas of combinatorial chemistry and drug delivery are in fact closely linked by Lilly's approach towards asset management.

You may also be interested in...



Inside Lilly Research Laboratories: A Discussion With Jan Lundberg

Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.

EU Advances Plans For New Catalogs Of RWD Sources & Non-Interventional Studies

Users of the new catalogs will benefit from a modern technology with enhanced view, search, export and data submission functionalities, says the European Commission.

US Court Says Yes To Gilead’s Quarter Billion Dollar Settlement On Truvada, Atripla

Despite winning a landmark multi-billion-dollar antitrust suit earlier this year, Gilead Sciences has seen a US court give an initial green light allowing it to shell out nearly $250m to settle antitrust claims from direct purchasers of its two major HIV drugs.

Topics

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV000641

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel